(Q38972343)

English

Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

immuno-oncology

1 reference

based on heuristic

inferred from title

author name string

A K S Salama

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

S J Moschos

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

publication date

1 January 2017

1 reference

Europe PubMed Central

8 September 2017

number of pages

18

1 reference

based on heuristic

inferred from page(s)

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

57-74

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cell exhaustion

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classifying Cancers Based on T-cell Infiltration and PD-L1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irradiation and immunotherapy: From concept to the clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological hallmarks of stromal cells in the tumour microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 blockade induces responses by inhibiting adaptive immune resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab in patients with melanoma and autoimmune disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genomic Classification of Cutaneous Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural innate and adaptive immunity to cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 regulates extrathymic regulatory T-cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Programmed death ligand-1 expression in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immune score as a new possible approach for the classification of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

RAC1 P29S regulates PD-L1 expression in melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus ipilimumab in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28177433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDW534

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6887913&resulttype=core&format=json

13 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38972343&oldid=1767034924"